SCHEMBL6715817

SCHEMBL6715817

Cc1ccc(-c2ccccc2)cc1NNC(=O)C(NC(=S)Nc1ccccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.46
ALOX12 P18054 5/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
PLA2G1B P04054 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
TP53 P04637 1/20 0.43
MAPT P10636 3/20 0.42
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ULK1 O75385 1/20 0.41
CYP3A4 P08684 1/20 0.40
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723529 0.93 ALDH1A1 (0.46) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9
SCHEMBL8347960 0.92 ALDH1A1 (0.48) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9
SCHEMBL8346900 0.86 ALDH1A1 (0.48) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9
SCHEMBL6714265 0.83 KMT2A (0.45) ALDH1A1ALOX12NPSR1CYP2C9CYP2C19
SCHEMBL6715497 0.82 ALDH1A1 (0.55) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9
SCHEMBL6821806 0.81 CASP2 (0.41) ALDH1A1MAPTGAANPC1RAB9A
SCHEMBL6714029 0.79 ALDH1A1 (0.52) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9
SCHEMBL6716815 0.78 ALDH1A1 (0.53) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9
SCHEMBL6715751 0.77 ALDH1A1 (0.52) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9
SCHEMBL6717041 0.76 ALOX12 (0.52) ALDH1A1ALOX12NPSR1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885ALOX12 2690/4885NPSR1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.